A paper from Shenzhen University and affiliated organizations covers the discovery of a novel bromodomain-containing protein 4 (BRD4)-specific proteolysis-targeting chimera (PROTAC).

Earlier this month, researchers from Molecure SA presented the discovery of a novel arginase inhibitor to be developed for the treatment of cancer.

Axcelead Drug Discovery Partners (DDP) Inc. has entered into a strategic research and collaboration agreement with Eli Lilly & Co. for multiple drug discovery programs.

Work at Sensei Biotherapeutics Inc. has led to the discovery of an anti-CD39 antibody dependent on pH in the TME, SNS-103.

Secondary progressive multiple sclerosis (SPMS) is a chronic form of disease that occurs after relapsing-remitting MS, with a progressive disease course, and its pathogenesis remains unclear. CX3C chemokine receptor 1 (CX3CR1) is a G protein-coupled receptor that may be a useful marker of Eomes+ Th cells; the antigen has been shown to be expressed by cytotoxic Th cells and required for late-onset disease.

Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership brings together Nanovation’s proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver, and Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.